Actelion to join the SMI (Swiss Market Index)

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




ALLSCHWIL, SWITZERLAND - 8 July 2008 - Actelion Ltd (SWX: ATLN)
announced today that the Management Committee of the SWX Swiss
Exchange has decided to add Actelion shares (ATLN, CH001053248) to
the Swiss Market Index SMI®. Actelion shares will trade for the first
time as part of the SMI on Monday, 22nd September 2008, when the SMI
basket adjustment will take place.

As a blue-chip index, the SMI is Switzerland's key equity index. It
represents about 85% of the free-float capitalization of the Swiss
equity market. The SMI comprises the 20 largest and most liquid
equities of the SPI® (Swiss Performance Index®). Since the SMI is
considered to be a mirror of the overall Swiss stock market, it is
used as the underlying index for numerous derivative financial
instruments such as options, futures and index funds (e.g. ETFs).

The composition of the SMI is examined - and - if appropriate -
updated once a year. More details about the index, the selection
process and past, current and future composition of the index are
available on the website of the SWX Swiss Exchange at www.swx.com

###

Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate
headquarters in Allschwil/Basel, Switzerland. Actelion's first drug
Tracleer®, an orally available dual endothelin receptor antagonist,
has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets Tracleer® through its own subsidiaries in key
markets worldwide, including the United States (based in South San
Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of
cells separating every blood vessel from the blood stream. Actelion's
over 1700 employees focus on the discovery, development and marketing
of innovative drugs for significant unmet medical needs. Actelion
shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
http://www.actelion.com



--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil
Switzerland

WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP,
SMIM, SPI, SPIEX;
Listed: Main Market in SWX Swiss Exchange;

View document